CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug Administration (FDA) did something that may enter the record books.

The FDA's acceptance of the CRISPR Therapeutics and Vertex files marks a first. It's the first time the FDA has agreed to review a candidate that relies on the CRISPR gene editing technique.

The potential product -- exa-cel for blood disorders -- may add to Vertex's blockbuster revenue. But for CRISPR Therapeutics, it could be even more important. Could it signal a big turning point for the biotech company? 

Continue reading

Source Fool.com